Adult Malignant Glioma Therapeutics Market Size (2024 - 2029)

Adult Malignant Glioma Therapeutics Market Analysis

The adult malignant glioma therapeutics market is projected to register a CAGR of 9.6% during the forecast period.

The COVID-19 pandemic has caused widespread disruption in cancer care, including delays in treatment as well as the suspension of clinical trials. For instance, according to an article published in June 2021, the provision of oncology services was considerably reduced during the COVID pandemic. COVID-19 also had an adverse impact on people with malignant brain tumors. For instance, an article published in Acta Medica in July 2022 stated that due to immunodepression related to tumor disease and anti-cancer treatments, cancer patients were more vulnerable to COVID-19 and had a higher risk of severe complications requiring intensive care. However, the market recovered in the past few years since the restrictions were lifted and trials for the development of glioma therapeutics resumed. COVID-19 has a negligible impact on the adult malignant glioma therapeutics market in the current scenario and is expected to show a stable growth rate during the forecast period.

The high burden of brain cancer and malignant gliomas globally is expected to propel market growth. For instance, according to the Canadian Cancer Society 2022 update, 3,200 Canadians were estimated to be diagnosed with brain and spinal cord cancer in 2022. Also, as per the Australian Institute of Health and Welfare 2022 report, the estimated age-standardized incidence rate for brain cancer was 6.4 cases per 100,000 persons (8.1 for males and 4.8 for females) in 2022.

Furthermore, the rising funding and engagement of government organizations to expedite the malignant gliomas therapeutics research and development (R&D) is also contributing significantly to the market growth. For instance, in October 2022, the Australian Government provided more than USD 5.4 million to support brain cancer research. The funding is from the Medical Research Future Fund (MRFF). Also, in September 2021, the NCI-funded Glioblastoma Therapeutics Network (GTN) reported working collaboratively to develop new treatments for malignant gliomas. The rising funding and partnership for the development of innovative therapeutics are expected to propel market growth.

The strategic initiatives by market players, such as product approvals, launches, and partnerships to expand adult malignant gliomas therapeutics, are expected to augment the market growth. For instance, in December 2021, Sapience Therapeutics, Inc. was granted Fast Track Designation to its lead program investigating ST101 for treating recurrent glioblastoma (GBM) by the United States Food and Drug Administration (FDA). The fast-track designation expedites the review of a drug for treating serious conditions, thereby propelling the market growth.

Therefore, owing to the factors such as the high burden of brain cancer, rising R&D spending, and product approvals and launches by market players, the studied market is anticipated to witness growth over the analysis period. However, the diminishing preference for chemotherapy and low approval rates for novel therapeutics for glioma is estimated to restrain the market growth.

Adult Malignant Glioma Therapeutics Industry Segmentation

As per the scope of the report, malignant brain tumors strike deep into the psyche of those receiving and those delivering the diagnosis. Malignant gliomas, the most common subtype of primary brain tumors, are aggressive, highly invasive, and neurologically destructive tumors considered to be among the deadliest of human cancers. The Adult Malignant Glioma Therapeutics Market is Segmented by Type of Disease (Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, and Other Types of Diseases), Therapy (Chemotherapy, Targeted Drug Therapy, and Radiation Therapy) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.